213 related articles for article (PubMed ID: 32079208)
1. Clarithromycin Versus Metronidazole in First-Line
Murata M; Sugimoto M; Mizuno H; Kanno T; Satoh K
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32079208
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance.
Dehesa M; Larisch J; Dibildox M; Di Silvio M; Lopez LH; Ramirez-Barba E; Torres J
Clin Drug Investig; 2002; 22(2):75-85. PubMed ID: 23315395
[TBL] [Abstract][Full Text] [Related]
3. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.
Puig I; Baylina M; Sánchez-Delgado J; López-Gongora S; Suarez D; García-Iglesias P; Muñoz N; Gisbert JP; Dacoll C; Cohen H; Calvet X
J Antimicrob Chemother; 2016 Oct; 71(10):2740-53. PubMed ID: 27342548
[TBL] [Abstract][Full Text] [Related]
5. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection.
Matsushima M; Suzuki T; Kurumada T; Watanabe S; Watanabe K; Kobayashi K; Deguchi R; Masui A; Takagi A; Shirai T; Muraoka H; Kobayashi I; Mine T
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):232-6. PubMed ID: 16460479
[TBL] [Abstract][Full Text] [Related]
6. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
7. Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant
Sue S; Suzuki Y; Sasaki T; Kaneko H; Irie K; Komatsu K; Maeda S
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685510
[TBL] [Abstract][Full Text] [Related]
8. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis.
Li B; Lan X; Wang L; Zhao J; Ding J; Ding H; Lei J; Wei Y; Zhang W
Microb Pathog; 2020 Feb; 142():104075. PubMed ID: 32074497
[TBL] [Abstract][Full Text] [Related]
9. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
10. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
Sue S; Kuwashima H; Iwata Y; Oka H; Arima I; Fukuchi T; Sanga K; Inokuchi Y; Ishii Y; Kanno M; Terada M; Amano H; Naito M; Iwase S; Okazaki H; Komatsu K; Kokawa A; Kawana I; Morimoto M; Saito T; Kunishi Y; Ikeda A; Takahashi D; Miwa H; Sasaki T; Tamura T; Kondo M; Shibata W; Maeda S
Intern Med; 2017; 56(11):1277-1285. PubMed ID: 28566587
[TBL] [Abstract][Full Text] [Related]
11. Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Kato S; Konno M; Maisawa S; Tajiri H; Yoshimura N; Shimizu T; Toyoda S; Nakayama Y; Iinuma K
J Gastroenterol; 2004 Sep; 39(9):838-43. PubMed ID: 15565402
[TBL] [Abstract][Full Text] [Related]
12. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility.
Miyaki A; Yamaguchi K; Ida A; Miyauchi T
Minerva Gastroenterol Dietol; 2016 Sep; 62(3):234-9. PubMed ID: 27304198
[TBL] [Abstract][Full Text] [Related]
13. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
Asaoka D; Nagahara A; Matsuhisa T; Takahashi S; Tokunaga K; Kawai T; Kawakami K; Suzuki H; Suzuki M; Nishizawa T; Kurihara N; Ito M; Sasaki H; Omata F; Mizuno S; Torii A; Ohkusa T; Mine T; Sakaki N
Helicobacter; 2013 Dec; 18(6):468-72. PubMed ID: 23773231
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan.
Mabe K; Okuda M; Kikuchi S; Amagai K; Yoshimura R; Kato M; Sakamoto N; Asaka M;
J Infect Chemother; 2018 Jul; 24(7):538-543. PubMed ID: 29605555
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant
Zou SP; Cheng Q; Feng CY; Xu C; Sun MH
World J Clin Cases; 2022 Dec; 10(35):12959-12970. PubMed ID: 36569016
[TBL] [Abstract][Full Text] [Related]
16. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
19. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
